SCHEDULE 13G/A: Meteora Capital and Vik Mittal Disclose 7.84% Beneficial Stake in NKGen Biotech

Meteora Capital, LLC and its Managing Member Vik Mittal have disclosed a beneficial ownership of 7.84% in NKGen Biotech, Inc.'s common stock as of December 31, 2024.

Summary

• Meteora Capital, LLC and Vik Mittal, as Reporting Persons, have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in NKGen Biotech, Inc.
• The filing indicates that Meteora Capital, LLC serves as the investment manager for certain funds and managed accounts (Meteora Funds) holding the Common Stock.
• Vik Mittal, as the Managing Member of Meteora Capital, also reports beneficial ownership with respect to the Common Stock held by the Meteora Funds.
• As of December 31, 2024, the Reporting Persons collectively beneficially own 2,772,145 shares of NKGen Biotech, Inc. Common Stock.
• This aggregate amount represents 7.84% of the issuer's Common Stock class.
• The Reporting Persons hold shared voting power and shared dispositive power over all 2,772,145 shares, with no sole voting or dispositive power.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: Neutral, as this is a factual disclosure of beneficial ownership and does not contain performance or strategic updates, nor does it imply any specific sentiment towards the issuer's future performance.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of beneficial ownership by an investment firm in a publicly traded company within the biotech sector. It does not provide specific insights into broader industry trends or competitive landscape, but rather reflects an investment decision by Meteora Capital in NKGen Biotech.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.
• Company Management: Awareness of a significant shareholder, though the filing states the stake is for ordinary course of business and not for control.

Key Dates

Keywords

NKGen Biotech, Meteora Capital, Vik Mittal, Beneficial Ownership, Schedule 13G, Common Stock, Investment Management, SEC Filing, Biotech